- Analysis
- Zacks Investment Research
NxStage Medical, Inc., a medical technology company, develops, manufactures and markets products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. It offers System One Cycle, a portable hemodialysis system, which is used primarily for home hemodialysis; PureFlow SL, offers water purification and dialysate production in one integrated unit, designed for use at home or in-center; chronic cartridges provides patient flexibility for more frequent, nocturnal, or intermittent renal replacement therapy at home; and Nx2me Connected Health, a telehealth platform for the collection and delivery of home hemodialysis treatment and patient medical information. It also offers bloodlines, needles, and dialysis fluids. The company provides dialysis services. It operates dialysis centers. NxStage Medical, Inc. was formerly known as QB Medical, Inc. The company was incorporated in 1998 and is based in Lawrence, Massachusetts. As of February 21, 2019, NxStage Medical, Inc. operates as a subsidiary of Fresenius Medical Care Holdings, Inc.